Conversion of bacterially expressed recombinant prion protein.

Area of Science:

• Neuroscience
• Biochemistry
• Infectious Diseases

Background:

• Prion diseases are neurodegenerative disorders characterized by protein misfolding and aggregation.
• The infectious agent in prion disease is the misfolded prion protein (PrPSc), which arises from the normal prion protein (PrPC).
• The conversion of PrPC to PrPSc is a key step in prion disease pathogenesis.

Purpose of the Study:

• To develop an in vitro method for studying prion protein conversion and infectivity.
• To investigate the molecular mechanisms underlying prion disease.

Main Methods:

• Utilized the Protein Misfolding Cyclic Amplification (PMCA) technique.
• Converted bacterially expressed recombinant PrP into a proteinase K-resistant and aggregated form (rPrP-res) using anionic lipids and RNA.
• Assessed infectivity of rPrP-res through intracerebral inoculation in wild-type mice.

Main Results:

• Successfully converted recombinant PrP into an aggregated and proteinase K-resistant form (rPrP-res) in vitro.
• Demonstrated high prion infectivity of rPrP-res in mice, leading to prion disease with a short incubation period.

Conclusions:

• Established a functional in vitro assay for recombinant prion protein conversion.
• This assay facilitates exploration of the molecular basis of prion infectivity and disease.
• Provides a novel tool for studying prion diseases and developing potential therapeutic strategies.